Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses.

ABSTRACT:

Purpose of review

There is growing consensus that eliciting CD8+ T cells in addition to antibodies may be required for an effective HIV vaccine for both prevention and cure. Here, we review key qualities of vaccine-elicited CD8+ T cells as well as major CD8+ T cell-based delivery platforms used in recent HIV vaccine clinical trials.

Recent findings

Much progress has been made in improving HIV immunogen design and delivery platforms to optimize CD8+ T cell responses. With regards to viral vectors, recent trials have tested newer chimp and human adenovirus vectors as well as a CMV vector. DNA vaccine immunogenicity has been increased by delivering the vaccines by electroporation and together with adjuvants as well as administering them as part of a heterologous regimen. In pre

SUBMITTER: Borgo GM 

PROVIDER: S-EPMC10552829 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature